Paper36948878
[Study progress of tyrosine kinase inhibitor discontinuation in children with chronic myeloid leukemia].
Zheng FY and 3 others. Zhonghua Xue Ye Xue Za Zhi, 2023. Cited by 0 papers, by iCite.
Cite this record
ConductScience Library. [Study progress of tyrosine kinase inhibitor discontinuation in children with chronic myeloid leukemia]. Papers, record 36948878. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/36948878
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- [Study progress of tyrosine kinase inhibitor discontinuation in children with chronic myeloid leukemia].
- PubMed
Topics6
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Tyrosine Kinase Inhibitors | Major topic |
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | Major topic |
| Humans | |
| Child | |
| Protein Kinase Inhibitors | |
| Chronic Disease |
Source PubMed
References20
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 34439257 | Discontinuation of Imatinib in Children with Chronic Myeloid Leukemia: A Study from the International Registry of Childhood CML. | Cancers (Basel) | 2021 | https://conductscience.org/library/papers/34439257 | PubMed |
| 2 | 24810322 | Sustained complete molecular remission after imatinib discontinuation in children with chronic myeloid leukemia. | Pediatr Blood Cancer | 2014 | https://conductscience.org/library/papers/24810322 | PubMed |
| 3 | 33672937 | Definition, Epidemiology, Pathophysiology, and Essential Criteria for Diagnosis of Pediatric Chronic Myeloid Leukemia. | Cancers (Basel) | 2021 | https://conductscience.org/library/papers/33672937 | PubMed |
| 4 | 28095277 | Long-Term Follow-Up of the French Stop Imatinib (STIM1) Study in Patients With Chronic Myeloid Leukemia. | J Clin Oncol | 2017 | https://conductscience.org/library/papers/28095277 | PubMed |
| 5 | 32072631 | Risk of molecular recurrence after tyrosine kinase inhibitor discontinuation in chronic myeloid leukaemia patients: a systematic review of literature with a meta-analysis of studies over the last ten years. | Br J Haematol | 2020 | https://conductscience.org/library/papers/32072631 | PubMed |
| 6 | 32087030 | Results and outcome of intermittent imatinib (ON/OFF schedule) in children and adolescents with chronic myeloid leukaemia. | Br J Haematol | 2020 | https://conductscience.org/library/papers/32087030 | PubMed |
| 7 | 24106110 | Imatinib cessation in children and adolescents with chronic myeloid leukemia in chronic phase. | Pediatr Blood Cancer | 2014 | https://conductscience.org/library/papers/24106110 | PubMed |
| 8 | 30843196 | Discontinuation of imatinib in children with chronic myeloid leukaemia in sustained deep molecular remission: results of the STOP IMAPED study. | Br J Haematol | 2019 | https://conductscience.org/library/papers/30843196 | PubMed |
| 9 | 33022644 | Chronic Myeloid Leukemia, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. | J Natl Compr Canc Netw | 2020 | https://conductscience.org/library/papers/33022644 | PubMed |
| 10 | 25160793 | Treatment-free remission after imatinib discontinuation is possible in paediatric patients with chronic myeloid leukaemia. | Br J Haematol | 2015 | https://conductscience.org/library/papers/25160793 | PubMed |
| 11 | 32127639 | European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. | Leukemia | 2020 | https://conductscience.org/library/papers/32127639 | PubMed |
| 12 | 33718985 | Chronic Myelogenous Leukemia in Childhood. | Curr Oncol Rep | 2021 | https://conductscience.org/library/papers/33718985 | PubMed |
| 13 | 28838993 | Prognostic discrimination based on the EUTOS long-term survival score within the International Registry for Chronic Myeloid Leukemia in children and adolescents. | Haematologica | 2017 | https://conductscience.org/library/papers/28838993 | PubMed |
| 14 | 20965785 | Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. | Lancet Oncol | 2010 | https://conductscience.org/library/papers/20965785 | PubMed |
| 15 | 34439327 | Treatment-Free Remission in Chronic Myeloid Leukemia: Can We Identify Prognostic Factors? | Cancers (Basel) | 2021 | https://conductscience.org/library/papers/34439327 | PubMed |
| 16 | 29459949 | Treatment-Free Remission After Second-Line Nilotinib Treatment in Patients With Chronic Myeloid Leukemia in Chronic Phase: Results From a Single-Group, Phase 2, Open-Label Study. | Ann Intern Med | 2018 | https://conductscience.org/library/papers/29459949 | PubMed |
| 17 | 31688623 | Discontinuation of Imatinib in a Child With Chronic Myeloid Leukemia. | J Pediatr Hematol Oncol | 2020 | https://conductscience.org/library/papers/31688623 | PubMed |
| 18 | 34714411 | Health-related quality of life in children with chronic myeloid leukemia in the chronic phase. | J Cancer Res Clin Oncol | 2022 | https://conductscience.org/library/papers/34714411 | PubMed |
| 19 | 23704092 | Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study. | Blood | 2013 | https://conductscience.org/library/papers/23704092 | PubMed |
| 20 | 35751859 | Chronic myeloid leukemia: 2022 update on diagnosis, therapy, and monitoring. | Am J Hematol | 2022 | https://conductscience.org/library/papers/35751859 | PubMed |
Genes1
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes |
|---|---|---|---|
| ABL1 | 25 | PubTator's text mining | https://conductscience.org/library/genes/25 |
Source NCBI Gene
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Cited by
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/36948878
GET https://conductscience.org/api/papers/v1/36948878/authors